23.88
2.81%
-0.69
After Hours:
23.88
Smith & Nephew plc ADR stock is currently priced at $23.88, with a 24-hour trading volume of 1.17M.
It has seen a -2.81% decreased in the last 24 hours and a -7.59% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $24.54 pivot point. If it approaches the $24.25 support level, significant changes may occur.
Previous Close:
$24.57
Open:
$24.36
24h Volume:
1.17M
Market Cap:
$10.44B
Revenue:
$5.55B
Net Income/Loss:
$263.00M
P/E Ratio:
47.76
EPS:
0.5
Net Cash Flow:
-
1W Performance:
-0.54%
1M Performance:
-7.59%
6M Performance:
+8.99%
1Y Performance:
-24.21%
Smith & Nephew plc ADR Stock (SNN) Company Profile
Name
Smith & Nephew plc ADR
Sector
Industry
Phone
44 20 7401 7646
Address
15 Adam Street, London
Smith & Nephew plc ADR Stock (SNN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
Oct-13-23 | Initiated | Stifel | Hold |
Aug-08-23 | Upgrade | UBS | Sell → Neutral |
Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-12-22 | Initiated | Citigroup | Buy |
Nov-28-22 | Downgrade | UBS | Neutral → Sell |
Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
Dec-01-20 | Initiated | Barclays | Overweight |
Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
Nov-21-19 | Initiated | Citigroup | Buy |
Nov-12-19 | Initiated | Bernstein | Outperform |
Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-11-17 | Initiated | Canaccord Genuity | Buy |
Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
Jan-19-17 | Initiated | HSBC Securities | Hold |
Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith & Nephew plc ADR Stock (SNN) Latest News
Smith+Nephew (SNN) Expands in Australia With New Alliance
Zacks Investment Research
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
GlobeNewswire Inc.
Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
GlobeNewswire Inc.
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
GlobeNewswire Inc.
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Zacks Investment Research
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
GlobeNewswire Inc.
Smith & Nephew plc ADR Stock (SNN) Financials Data
Smith & Nephew plc ADR (SNN) Revenue 2024
SNN reported a revenue (TTM) of $5.55 billion for the quarter ending December 31, 2023, a +6.47% rise year-over-year.
Smith & Nephew plc ADR (SNN) Net Income 2024
SNN net income (TTM) was $263.00 million for the quarter ending December 31, 2023, a -49.81% decrease year-over-year.
Smith & Nephew plc ADR (SNN) Earnings per Share 2024
SNN earnings per share (TTM) was $0.602 for the quarter ending December 31, 2023, a -49.46% decline year-over-year.
About Smith & Nephew plc ADR
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):